PISCATAWAY, N.J., Sept. 15, 2024 /PRNewswire/ — The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a new era for solid tumor treatment using cell therapy. PM359, the world’s first lead editing therapy, has been […]
Category Archives: Pr Newswire
LOS ANGELES, Sept. 15, 2024 /PRNewswire/ — To mark World First Aid Day on September 14th, themed “First Aid and Sports,” Rhino Rescue, the renowned professional first aid brand, has proudly unveiled the Rhino Rescue First Aid Kit for Outdoor. Aimed at bolstering safety and providing professional first aid kits for outdoor sports enthusiasts, this […]
RIYADH, Saudi Arabia, Sept. 14, 2024 /PRNewswire/ — The Global AI Summit (GAIN) in Riyadh concluded on a high, after the summit welcomed more than 30,000 delegates from across the globe over three days. The live stream of the summit, organized by the Saudi Data and AI Authority (SDAIA), received 3.7m views. Global AI Summit Calls […]
Swim with Giants: Experience Whale Sharks Like Never Before with This Pro-Level Vlog Smartphone! HONG KONG, Sept. 14, 2024 /PRNewswire/ — What is it like to swim alongside the largest fish on Earth? Now, moments like this can be captured in real-time on the screen of the Infinix ZERO 40 5G as users dive deep […]
AMSTERDAM, Sept. 14, 2024 /PRNewswire/ — Saramonic, a leading power in audio technology, released its latest wireless intercom headset system, the WiTalk9 Series, at a product launch event Team Talk, Now WiTalk at IBC 2024. This groundbreaking product was recognized as the Best in Show awards nominee by CineD, a professional review platform, and it set to elevate team […]
14
Sep
Sep
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, presented updates for its T cell receptor (TCR) library targeting the Kirsten rat sarcoma viral oncogene homolog (KRAS) and also […]
14
Sep
Sep
RIYADH, Saudi Arabia, Sept. 14, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC) is redefining patient engagement and care through its pioneering Experience Ambassadors Program. This initiative empowers selected employees to become ‘ambassadors’ from various departments, lead improvement projects, monitor service standards, and address critical patient satisfaction factors. This approach optimizes […]
Pr Newswire
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
14
Sep
Sep
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations treated with zipalertinib who progressed on or after prior amivantamab treatment Enrollment of pivotal Phase 2b trial complete ahead of schedule CAMBRIDGE, Mass., Sept. 14, 2024 […]
Pr Newswire
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
14
Sep
Sep
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline chemotherapy and the remainder are treated with osimertinib or afatinib Short time to treatment discontinuation ranging from four to eight months demonstrates clear unmet […]
Pr Newswire
RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
14
Sep
Sep
Post-progression outcomes showed significant and sustained improvement for amivantamab plus chemotherapy versus chemotherapy alone1 BEERSE, BELGIUM , Sept. 14, 2024 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson & Johnson company, today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT®▼ (amivantamab) combined with chemotherapy led to consistent benefit across post-progression outcomes […]